Medicinal herbs: Drugs or dietary supplements?

Biochemical Pharmacology

Volumn 59, Issue 3, 2000, Pages 211-219

  Chang, Joseph ^a  

^a Pharmanex Inc   (United States)

Author keywords

Clinical trials; Dietary supplements; Medicinal herbs; The Dietary Supplement Health and Education Act (DSHEA)

Indexed keywords

PLANT EXTRACT;

DIET SUPPLEMENTATION; DRUG EFFICACY; DRUG SAFETY; HERB; HERBAL MEDICINE; PRIORITY JOURNAL; REVIEW;

CLINICAL TRIALS; DIETARY SUPPLEMENTS; DRUG APPROVAL; FORECASTING; HUMANS; PHYTOTHERAPY; PLANT EXTRACTS; PLANTS, MEDICINAL; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 0033987220     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(99)00243-9     Document Type: Review

References (72)

1. Bauer U. Six-month double-blind randomized clinical trial of Ginkgo biloba extract versus placebo in two parallel groups in patients suffering from peripheral arterial insufficiency. Drug Res. 34:1984;716-720.
2. Kleijnen J., Knipschild P. Ginkgo biloba. Lancet. 340:1992;1136.
3. Harrer G., Schulz V. Clinical investigation of the antidepressant effectiveness of hypericum. J Geriatr Psychiatry Neurol. 7:1994;S6-S8.
4. Chang J.Y., Chang M.N. Medicinal uses of Ginkgo biloba. Todays Ther Trends. 15:1997;63-74.
5. LeBars PL, Katz MM, Berman N, Itil TM, Freedman AM and Schatzberg AF, A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. JAMA 278: 1327-1139, 1997.
6. DeSmet P.A.G.M., Nolen W.A. St. John's wort as an antidepressant. BMJ. 313:1996;241-242.
7. Martinez B., Kasper S., Ruhrmann S., Möller H.J. Hypericum in the treatment of seasonal affective disorders. J Geriatr Psychiatry Neurol. 7:1994;S29-S33.
8. Linde K., Ramirez G., Mulrow C.D., Pauls A., Weidenhammer W., Melchart D. St. John's Wort for depression - An overview and meta-analysis of randomised clinical trials. BMJ. 313:1996;253-258.
9. rd Congress, 2nd session, 1994.
10. McNamara S.H. Dietary supplements of botanicals and other substances A new era of regulation . Food Drug Law J. 50:1995;341-355.
11. Li C.L., Wong Y.Y. The bioavailability of ginkgolides in Ginkgo biloba extracts. Planta Med. 63:1997;487-584.
12. Spilker B. Guide to Clinical Trials. 1996;Lippincott-Raven, Philadelphia.
13. Nadir A., Agrawal S., King P.D., Marshall J.B. Acute hepatitis associated with the use of a Chinese herbal product, Ma-Huang. Am J Gastroenterol. 91:1996;1436-1438.
14. Powell T., Hsu F.F., Turk J., Hruska K. Ma-Huang strikes again Ephedrine nephrolithiasis . Am J Kidney Dis. 32:1998;153-159.
15. Ved H.S., Koenig M.L., Dave J.R., Doctor B.P. Huperzine A, a potential therapeutic agent for dementia, reduces neuronal cell death caused by glutamate. Neuroreport. 8:1997;963-968.
16. Grunwald J., Raveh L., Doctor B.P., Ashani Y. Huperzine A as a pretreatment candidate drug against nerve agent toxicity. Life Sci. 54:1994;991-997.
17. Zhu X.D., Giacobini E. Second generation cholinesterase inhibitors Effect of (L)-huperzine-A on cortical biogenic amines . J Neurosci Res. 41:1995;828-835.
18. Ashani Y., Grunwald J., Kronman C., Velan C.B., Shafferman A. Role of tyrosine 337 in the binding of huperzine A to the active site of human acetylcholinesterase. Mol Pharmacol. 45:1994;555-560.
19. Raves M.L., Harel M., Pang Y.P., Silman I., Kozikowski A.P., Sussman J.L. Structure of acetylcholinesterase complexed with the nootropic alkaloid, (-)-huperzine A. Nat Struct Biol. 4:1997;57-63.
20. Hesseltine C.W. The future of fermented foods. Nutr Rev. 41:1983;293-301.
21. Sung YH, T'ien Kung K'ai-Wu; Chinese Technology in the Seventeenth Century. Eds. Sun ET and Sun SC, pp. 291-294. Pennsylvania State University Press, University Park, 1966.
22. Li C.L., Zhu Y., Wang Y.Y., Zhu J.S., Chang J., Kritchevsky D. Monascus purpureus (red yeast) A natural product that lowers blood cholesterol in animal models of hypercholesterolemia . Nutr Res. 18:1998;71-81.
23. Wang J., Lu Z., Chi J., Wang W., Su M., Kou W., Yu P., Yu L., Chen L., Zhu J.-S., Chang J. Multicenter clinical trial of the serum lipid-lowering effects of a Monascus purpureus (red yeast) rice preparation from traditional Chinese medicine. Curr Ther Res. 58:1997;964-978.
24. Shen Z., Yu P., Sun M., Chi J., Zhou Y., Zhu X., Yang C., He C. Treatment of primary hyperlipidemia with Zhitai (Xuezhikang) capsule A pilot clinical study . Natl Med J China. 76:1996;156-157.
25. Heber D., Yip I., Ashley J.M., Elashoff D.A., Elashoff R., Go V.L.W. Cholesterol-lowering effects of a proprietary Chinese red yeast rice dietary supplement. Am J Clin Nutr. 69:1999;231-236.
26. Endo A. Monacolin K, a new hypocholesterolemic agent produced by a Monascus species. J Antibiot (Tokyo). 32:1979;852-854.
27. Yang C.S., Wang Z.Y. Tea and cancer. J Natl Cancer Inst. 85:1993;1038-1049.
28. Mitscher L.A., Jung M., Shankel D., Dou J.H., Steele L., Pillai S.P. Chemoprotection A review of the potential therapeutic antioxidant properties of green tea (Camellia sinensis) and certain of its constituents . Med Res Rev. 17:1997;327-365.
29. Chen Z.P., Schell J.B., Ho C.T., Chen K.Y. Green tea epigallocatechin gallate shows a pronounced growth inhibitory effect on cancerous cells but not on their normal counterparts. Cancer Lett. 129:1998;173-179.
30. Ahmad N., Feyes D.K., Nieminen A.-L., Agarwal R., Muktar H. Green tea constituent epigallocatechin-3-gallate and induction of apoptosis and cell cycle arrest in human carcinoma cells. J Natl Cancer Inst. 89:1997;1881-1886.
31. Zhao B.L., Li X.J., He R.G., Cheng S.J., Xin W.J. Scavenging effect of extracts of green tea and natural antioxidants on active oxygen radicals. Cell Biophys. 14:1989;175-185.
32. Chen J. The effects of Chinese tea on the occurrence of esophageal tumors induced by N-nitrosomethylbenzylamine in rats. Prev Med. 21:1992;385-391.
33. Khan S.G., Katiyar S.K., Agarwal R., Mukhtar H. Enhancement of antioxidant and phase II enzymes by oral feeding of green tea polyphenols in drinking water to SKH-1 hairless mice Possible role in cancer chemoprevention . Cancer Res. 52:1992;4050-4052.
34. Wang Z.Y., Cheng S.J., Zhou Z.C., Athar M., Khan W.A., Bickers D.R., Mukhtar H. Antimutagenic activity of green tea polyphenols. Mutat Res. 223:1989;273-285.
35. Wang Z.Y., Khan W.A., Bickers D.R., Mukhtar H. Protection against polycyclic aromatic hydrocarbon-induced skin tumor initiation in mice by green tea polyphenols. Carcinogenesis. 10:1989;411-415.
36. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans Coffee, tea, mate, methylxanthines and methylglyoxal . IARC Monogr Eval Carcinog Risks Hum. 51:1991;7-513.
37. Yu G.P., Hsieh C.C., Wang L.Y., Yu S.Z., Li X.L., Jin T.H. Green-tea consumption and risk of stomach cancer A population-based case-control study in Shanghai, China . Cancer Causes Control. 6:1995;532-538.
38. Gao Y.T., McLaughlin J.K., Blot W.J., Ji B.T., Dai Q., Fraumeni J.F. Jr. Reduced risk of esophageal cancer associated with green tea consumption. J Natl Cancer Inst. 86:1994;855-858.
39. Ji B.-T., Chow W.-H., Yang G., McLaughlin J.K., Gao R.-N., Zheng W., Shu X.-O., Jin F., Fraumeni J.F. Jr, Gao Y.-T. The influence of cigarette smoking, alcohol, and green tea consumption on the risk of carcinoma of the cardia and distal stomach in Shanghai, China. Cancer. 77:1996;2449-2457.
40. Kono S., Ikeda M., Tokudome S., Kuratsune M. A case-control study of gastric cancer and diet in northern Kyushu, Japan. Jpn J Cancer Res. 79:1988;1067-1074.
41. Ji B.-T., Chow W.-H., Hsing A.W., McLaughlin J.K., Dai Q., Gao Y.-T., Blot W.J., Fraumeni J.F. Jr. Green tea consumption and the risk of pancreatic and colorectal cancers. Int J Cancer. 70:1997;255-258.
42. Kato I., Tominaga S., Matsuura A., Yoshii Y., Shirai M., Kobayashi S. A comparative case-control study of colorectal cancer and adenoma. Jpn J Cancer Res. 81:1990;1101-1108.
43. Morré D.J., Chueh P.-J., Morré D.M. Capsaicin inhibits preferentially the NADH oxidase and growth of transformed cells in culture. Proc Natl Acad Sci USA. 92:1995;1831-1835.
44. Morré D.J., Sun E., Geilen C., Wu L.-Y., de Cabo R., Krasagakis K., Orfanos C.E., Morré D.M. Capsaicin inhibited plasma membrane NADH oxidase and growth of human and mouse melanoma lines. Eur J Cancer. 32A:1996;1995-2003.
45. Yantiri F., Morré D.J., Yagiz K., Barogi S., Wang S., Chueh P.-J., Cho N., Sedlak D., Morré D.M. Capsaicin-responsive NADH oxidase activities from urine of cancer patients. Arch Biochem Biophys. 358:1998;336-342.
46. Paschka A.G., Butler R., Young C.Y. Induction of apoptosis in prostate cancer cell lines by the green tea component, (-)-epigallocatechin-3-gallate. Cancer Lett. 130:1998;1-7.
47. Naasani I., Seimiya H., Tsuruo T. Telomerase inhibition, telomere shortening, and senescence of cancer cells by tea catechins. Biochem Biophys Res Commun. 249:1998;391-396.
48. Lavie G., Mazur Y., Lavie D., Meruelo D. The chemical and biological properties of hypericin - a compound with a broad spectrum of biological activities. Med Res Rev. 15:1995;111-119.
49. Neary J.T., Bu Y. Hypericum LI 160 inhibits uptake of serotonin and norepinephrine in astrocytes. Brain Res. 816:1999;358-363.
50. Simmen U., Burkard W., Berger K., Schaffner W., Lundstrom K. Extracts and constituents of Hypericum perforatum inhibit the binding of various ligands to recombinant receptors expressed with the Semliki Forest virus system. J Recept Signal Transduct Res. 19:1999;59-74.
51. Kleber E., Obry T., Hippeli S., Schneider W., Elstner E. Biochemical activities of extracts from Hypericum perforatum L. Inhibition of dopamine-beta-hydroxylase. Arzneimittelforschung. 49:1999;106-109.
52. Assefa Z., Vantieghem A., Declercq W., Vandenabeele P., Vandenheede J.R., Merlevede W., de Witte P., Agostinis P. The activation of the c-Jun N-terminal kinase and p38 mitogen-activated protein kinase signaling pathways protects HeLa cells from apoptosis following photodynamic therapy with hypericin. J Biol Chem. 274:1999;8788-8796.
53. Gulick R.M., McAuliffe V., Holden-Wiltse J., Crumpacker C., Liebes L., Stein D.S., Meehan P., Hussey S., Forcht J., Valentine F.T. Phase I studies of hypericin, the active compound in St. John's Wort, as an antiretroviral agent in HIV-infected adults. AIDS Clinical Trials Group Protocols 150 and 258. Ann Intern Med. 130:1999;510-514.
54. Carraro J.-C., Raynaud J.-P., Koch G., Chisholm G.D., Di Silverio F., Teillac P., Da Silva F.C., Cauquil J., Chopin D.K., Hamdy F.C., Hanus M., Hauri D., Kalinteris A., Marencak J., Perier A., Perrin P. Comparison of phytotherapy (Permixon®) with finasteride in the treatment of benign prostate hyperplasia A randomized international study of 1,098 patients . Prostate. 29:1996;231-240.
55. Wilt T.J., Ishani A., Stark G., MacDonald R., Lau J., Mulrow C. Saw palmetto extracts for treatment of benign prostatic hyperplasia A systematic review . JAMA. 280:1998;1604-1609.
56. Weisser H., Tunn S., Behnke B., Krieg M. Effects of the Sabal serrulata extract IDS 89 and its subfractions on 5α-reductase activity in human benign prostatic hyperplasia. Prostate. 28:1996;300-306.
57. Rhodes L., Primka R.I., Berman C., Vergult G., Gabriel M., Pierre-Malice M., Gibelin B. Comparison of finasteride (Proscar®), a 5α reductase inhibitor, and various commercial plant extracts in in vitro and in vivo 5α reductase inhibition. Prostate. 22:1993;43-51.
58. Carilla E., Briley M., Fauran F., Sultan C., Duvilliers C. Binding of Permixon, a new treatment for prostatic benign hyperplasia, to the cytosolic androgen receptor in the rat prostate. J Steroid Biochem. 20:1984;521-523.
59. Braquet P. Proofs of involvement of PAF-acether in various immune disorders using BN 52021 (ginkgolide B) A powerful PAF-acether antagonist isolated from Ginkgo biloba L . Adv Prostaglandin Thromboxane Leukot Res. 16:1986;179-198.
60. Smith P.F., Maclennan K., Darlington C.L. The neuroprotective properties of the Ginkgo biloba leaf A review of the possible relationship to platelet-activating factor (PAF) . J Ethnopharmacol. 50:1996;131-139.
61. Pierre S., Jamme I., Droy-Lefaix M.T., Nouvelot A., Maixent J.M. Ginkgo biloba extract (EGb 761) protects Na,K-ATPase activity during cerebral ischemia in mice. Neuroreport. 10:1999;47-51.
62. Sasaki K., Hatta S., Haga M., Ohshika H. Effects of bilobalide on γ-aminobutyric acid levels and glutamic acid decarboxylase in mouse brain. Eur J Pharmacol. 367:1999;165-173.
63. Chen X., Salwinski S., Lee T.J. Extracts of Ginkgo biloba and ginsenosides exert cerebral vasorelaxation via a nitric oxide pathway. Clin Exp Pharmacol Physiol. 24:1997;958-959.
64. Kobuchi H., Droy-Lefaix M.T., Christen Y., Packer L. Ginkgo biloba extract (EGb 761) Inhibitory effect on nitric oxide production in the macrophage cell line RAW 264.7 . Biochem Pharmacol. 53:1997;897-903.
65. Burger R.A., Torres A.R., Warren R.P., Caldwell V.D., Hughes B.G. Echinacea-induced cytokine production by human macrophages. Int J Immunopharmacol. 7:1997;371-379.
66. Elsasser-Beile U., Willenbacher W., Bartsch H.H., Gallati H., Schulte Monting J., von Kleist S. Cytokine production in leukocyte cultures during therapy with Echinacea extract. J Clin Lab Anal. 10:1996;441-445.
67. Thompson K.D. Antiviral activity of Viracea against acyclovir susceptible and acyclovir resistant strains of herpes simplex virus. Antiviral Res. 39:1998;55-61.
68. Melchart D., Linde K., Worku F., Sarkady L., Holzmann M., Jurcic K., Wagner H. Results of five randomized studies on the immunomodulatory activity of preparations of Echinacea. J Altern Complement Med. 1:1995;145-160.
69. Melchart D., Walther E., Linde K., Brandmaier R., Lersch C. Echinacea root extracts for the prevention of upper respiratory tract infections A double-blind, placebo-controlled randomized trial . Arch Fam Med. 7:1998;541-545.
70. Watson J.A., Fang M., Lowenstein J.M. Tricarballylate and hydroxycitrate Substrate and inhibitor of ATP:citrate oxaloacetate lyase . Arch Biochem Biophys. 135:1969;209-217.
71. Watson J.A., Lowenstein J.M. Citrate and the conversion of carbohydrate into fat. Fatty acid synthesis by a combination of cytoplasm and mitochondria. J Biol Chem. 245:1970;5993-6002.
72. Heymsfield S.B., Allison D.B., Vasselli J.R., Pietrobelli A., Greenfield D., Nunez C. Garcinia cambogia (hydroxycitric acid) as a potential antiobesity agent A randomized controlled trial . JAMA. 280:1998;1596-1600.